The Increased Approval of Oral Oncolytics: 1995-2018

Christopher Russell, PharmD Candidate 2020, Joshua Nubla, PharmD
Albany College of Pharmacy and Health Sciences, National Community Oncology Dispensing Association, Inc.

Background
- NCODA is a patient-centered organization that ultimately aims to aid and educate practices to help patients throughout their treatment with oral oncology medications.
- The treatment of cancer via oral route (tablet/capsule) is increasing in prevalence in the clinical and outpatient settings.
- Oral medications used for the treatment of cancer are both unique and challenging, which results in increased importance of provider education to ensure safe treatment for patients.

Objectives
- Examine the growth of approval of oral oncology medications
- Identify years where approval of oral oncolytics spike
- Understand how and where oral oncyltics fit into the group of oncology medications across dosage forms
- Demonstrate need for oral oncology support

Methods
- Using information available from the National Institute of Health’s National Cancer Institute, a list was compiled of all medications with an approved indication for the treatment of cancer and its affiliated indications. This was a comprehensive list, including medications of all routes, such as oral, intravenous, etc.
- A second list was then formed, comprised strictly of oral oncolytics, or oral medications with an approved indication for the treatment of cancer from 1995-2018
- These lists were analyzed as individuals, analyzed as comparators, and extrapolated onto one another for further analysis. This was an evaluative study and IRB approval was not required.

Oncolytics Approval Data
- Number of Oral Oncolytics Approved per Year (1995-2018)
- Oral Oncolytics Approved from 2011-2018 vs Total Oral Oncolytics Approved
- Ratio of Oral Oncolytic Approvals (2018)

Discussion
- Per the NIH, there are a total of 252 medications with approved indications for the treatment of cancer.
- 98 of said medications are oral oncyltics as of 2018; rising from 11 in 2000.
- Approval of oral oncyltics has most noticeably increased since 2011, with 68.4% of oral oncyltics being approved since that time.
- From 2012-2018, four individual years accounted for the approval of at least 10 oral oncyltics

Conclusion
- Approval rates and the volume of oral oncyltics is trending in an exponential-like manner.
- To adjust to this increase, providers and patients need to be increasingly educated on these medications.
- NCODA and organizations like it are of upmost importance to help ensure safe use of the medications in a rapidly growing market.

References
- https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology
- https://www.cancer.gov/about-cancer/treatment/drugs